Paradigm Health secures $78M Series B to scale clinical trials!!

Paradigm Health today announced an oversubscribed $78M Series B financing, led by ARCH Venture Partners, to accelerate embedding clinical trials into routine care across the U.S. and globally. The round also included participation from new investor DFJ Growth and existing backers, including F-Prime, General Catalyst, GV (Google Ventures), Lux Capital and Mubadala Capital, as well as the American Cancer Society's BrightEdge Fund, underscoring durable conviction in platform-driven research enablement.

Paradigm Health's platform reimagines trial logistics by embedding AI-enabled patient matching and site feasibility into everyday clinical workflows, cutting complexity and cost. The company notes that trials are frequently bottlenecked by fragmented data and administrative overhead, and its solution aims to align trial activities with existing patient care pathways to accelerate progress.

Since expanding after acquiring Flatiron Health's Clinical Research Business, Paradigm Health now operates the largest oncology research network in the United States and is rapidly extending into neuroscience, cardiovascular, metabolic, and other therapeutic areas. The expanding network spans 45 states, 166 healthcare provider organizations, and 2,100 care locations, placing 70% of the U.S. cancer population within easy reach of a trial site.

Investment rationale centers on the industry’s demand for faster, more efficient trials as biopharmaceuticals push specialty therapies to market. The fresh funds will power expansion into additional geographies and support health systems eager to offer trials in closer proximity to routine care, addressing underrepresentation in research and shortening development timelines.

Leading-edge investors view Paradigm Health as a platform play at the intersection of care delivery and research. The round’s lead from ARCH Venture Partners signals appetite for infrastructure plays in life sciences; participant contributions from DFJ Growth, General Catalyst, GV, Lux Capital, and Mubadala Capital reflect confidence across traditional venture, strategic, and growth investors. The involvement of the BrightEdge Fund underscores strategic interest from industry-aligned funds.

From a market perspective, the shift toward real-world data, decentralized trial designs, and AI-powered trial operations is accelerating. The global clinical trials market remains substantial and under pressure to shorten development cycles, while patient access expands as research is embedded into community care settings. Paradigm Health's momentum positions it to influence how care delivery networks participate in clinical science and how patients gain faster access to novel therapies.